东北制药(000597) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥2,020,281,646.06, representing a 4.17% increase compared to ¥1,939,457,126.22 in the same period last year[9]. - Net profit attributable to shareholders was ¥38,682,048.63, a significant increase of 297.26% from a loss of ¥19,670,303.94 in the previous year[9]. - The net profit after deducting non-recurring gains and losses was ¥38,801,948.05, up 20.80% from ¥32,121,706.28 year-on-year[9]. - Basic earnings per share rose to ¥0.029, compared to a loss of ¥0.020 in the previous year, marking a 245.00% increase[9]. - The company's total operating revenue for the current period is CNY 545,479,286.46, an increase from CNY 503,402,619.64 in the previous period, representing a growth of approximately 8.3%[67]. - The operating profit for the current period is CNY 62,545,200.73, compared to CNY 53,695,010.44 in the previous period, indicating an increase of about 16.5%[63]. - The net profit for the current period is CNY 39,050,465.96, a significant recovery from a net loss of CNY 16,651,935.65 in the previous period[63]. - The total comprehensive income for the current period is CNY 39,179,214.84, a recovery from a loss of CNY -16,494,824.94 in the previous period[66]. Cash Flow - The net cash flow from operating activities improved to -¥19,140,586.66, a 92.76% increase compared to -¥264,423,012.13 in the same period last year[9]. - Cash inflow from operating activities totaled 1,863,441,967.54, down from 2,074,474,589.51 in the previous period[77]. - Cash received from sales of goods and services was 1,804,389,225.20, compared to 1,924,913,245.09 in the prior period, reflecting a decline[73]. - Cash outflow from operating activities totaled 1,882,582,554.20, compared to 2,338,897,601.64 in the previous period[77]. - Cash flow from investment activities resulted in a net outflow of -26,275,137.62, worsening from -9,741,992.18 in the previous period[77]. - Cash received from borrowings was 2,120 million yuan, an increase of 43% compared to the same period last year, mainly due to an increase in bank loans[21]. - The net increase in cash and cash equivalents was 189,864,336.08, a significant decrease from 1,116,793,693.16 in the prior period[79]. Assets and Liabilities - Total assets at the end of the reporting period were ¥13,359,287,232.48, reflecting a 9.81% increase from ¥12,165,694,782.80 at the end of the previous year[9]. - The total liabilities increased to CNY 9,087,623,989.03 from CNY 8,043,488,704.77, reflecting a growth of about 13%[48]. - The non-current liabilities rose to CNY 1,002,163,979.81 from CNY 727,283,562.15, marking an increase of about 37.6%[48]. - The total current liabilities rose to CNY 5,111,087,329.78 from CNY 4,712,771,960.89, indicating an increase of about 8.5%[54]. - The company's cash and cash equivalents amounted to CNY 734,736,312.47, compared to CNY 559,328,173.19 in the previous period, showing a growth of around 31%[49]. - Total current assets as of March 31, 2021, amounted to 6,785.36 million yuan, an increase from 5,553.15 million yuan as of December 31, 2020[40]. Expenses - The company's R&D expenses for the period were ¥11,350,000, a decrease of 32% compared to the same period last year[20]. - Operating expenses for the current period amounted to 10.01 million yuan, a decrease of 85% compared to the same period last year, primarily due to the impact of donations made during the pandemic last year[21]. - Income tax expenses for the current period were 13.99 million yuan, an increase of 320% year-on-year, mainly due to the increase in total profit[21]. - The total operating costs increased to CNY 1,951,610,102.16 from CNY 1,879,467,935.05, reflecting an increase of about 3.8%[63]. - The company's financial expenses rose to CNY 19,695,331.08 from CNY 18,469,461.79, an increase of approximately 6.7%[63]. - The tax expenses for the current period increased to CNY 21,470,519.27 from CNY 18,128,548.74, an increase of approximately 12.9%[63]. Shareholder Information - The total number of shareholders at the end of the reporting period was 36,625, with the largest shareholder holding 24.36% of the shares[13]. - The total equity attributable to shareholders reached CNY 4,129,693,896.42, up from CNY 3,980,603,910.63, indicating an increase of about 3.7%[48]. Other Information - The company received government subsidies amounting to ¥9,986,856.11 during the reporting period[20]. - The company has not disclosed any new product launches or technological advancements in this report[89]. - There were no significant market expansion or acquisition strategies mentioned in the earnings call[89]. - The first quarter report was not audited, indicating preliminary financial results[94].